Revvity Inc.
RVTY Healthcare Diagnostics & Research
Revvity Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 3.67% from fiscal 2024. In the quarter to June 2026, revenue grew 1.31%, EPS grew 2.17%, free cash flow grew 59.3% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.
Follow RVTY
Revvity Inc. (RVTY) Return on invested capital
Revvity Inc.'s return on invested capital over the twelve months to 30 June 2026 was 2.38%, up 0.1 percentage points from fiscal 2025 (2.33%). Over the past ten years it has ranged from 1.85% (fiscal 2023) to 10.2% (fiscal 2020); the current reading is higher than 27% of that period. That is above the Diagnostics & Research industry median of 0.00% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 2.33% | 0.09 |
| FY2024 | 2.24% | 0.39 |
| FY2023 | 1.85% | (2.25) |
| FY2022 | 4.10% | (2.73) |
| FY2021 | 6.83% | (3.35) |
| FY2020 | 10.2% | 5.36 |
| FY2019 | 4.82% | 0.13 |
| FY2018 | 4.69% | 0.40 |
| FY2017 | 4.29% | (2.19) |
| FY2016 | 6.48% | 1.04 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| DGX Quest Diagnostics Incorporated compare | 7.94% |
| QGEN QIAGEN N.V. compare | 6.62% |
| LH Labcorp Holdings Inc. compare | 6.50% |
| RVTY Revvity Inc. | 2.38% |
| ICLR ICON PLC compare | 1.57% |
| CRL Charles River Laboratories International, Inc. compare | 1.07% |
| MEDP Medpace Holdings, Inc. compare | 0.00% |
| TWST Twist Bioscience Corporation compare | −30.8% |
| GH Guardant Health, Inc. compare | −129.7% |
| Diagnostics & Research industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on RVTY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement